Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden | Zendy

Matthew D. Hellmann | Zendy; TudorEliade Ciuleanu | Zendy; Adam Płużański | Zendy; Jong Seok Lee | Zendy; Gregory A. Otterson | Zendy; Clarisse Audigier-Valette | Zendy; Elisa Minenza | Zendy; Helena Linardou | Zendy; Sjaak A. Burgers | Zendy; Pamela Salman | Zendy; Hossein Borghaei | Zendy; Suresh S. Ramalingam | Zendy; Julie R. Brahmer | Zendy; Martin Reck | Zendy; Kenneth J. O’Byrne | Zendy; William J. Geese | Zendy; George Green | Zendy; Chang Han | Zendy; Joseph D. Szustakowski | Zendy; Prabhu Bhagavatheeswaran | Zendy; Diane Healey | Zendy; Yali Fu | Zendy; Faith E. Nathan | Zendy; Luis PazAres | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Author(s) -

Matthew D. Hellmann,

TudorEliade Ciuleanu,

Adam Płużański,

Jong Seok Lee,

Gregory A. Otterson,

Clarisse Audigier-Valette,

Elisa Minenza,

Helena Linardou,

Sjaak A. Burgers,

Pamela Salman,

Hossein Borghaei,

Suresh S. Ramalingam,

Julie R. Brahmer,

Martin Reck,

Kenneth J. O’Byrne,

William J. Geese,

George Green,

Chang Han,

Joseph D. Szustakowski,

Prabhu Bhagavatheeswaran,

Diane Healey,

Yali Fu,

Faith E. Nathan,

Luis PazAres

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1801946

Subject(s) - nivolumab , ipilimumab , lung cancer , medicine , oncology , chemotherapy , cancer , immunotherapy

Nivolumab plus ipilimumab showed promising efficacy for the treatment of non-small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of benefit. In this part of an open-label, multipart, phase 3 trial, we examined progression-free survival with nivolumab plus ipilimumab versus chemotherapy among patients with a high tumor mutational burden (≥10 mutations per megabase).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research